Icosapent ethyl associated with plaque regression
Small trial shows regression of several plaque components, authors report
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.
Taking icosapent ethyl daily in addition to a statin and following a low cholesterol diet may lead to regression of atherosclerotic plaque, a small trial shows.
In the EVAPORATE trial, reported at the European Society of Cardiology’s virtual congress (ESC 2020) this week, 80 people with manifest coronary atherosclerosis were randomised to either 4g of icosapent ethyl or